A pilot clinical trial examining Marinomed’s antiviral nasal spray, which contains carrageenan, has indicated that it is effective as a treatment against the common cold. 12 August 2010
Some of pharmaceutical’s big boys, for example Pfizer, have faced well-documented challenges over the last 12 months. The industry is only too aware of this and understands that now is the time to look at new processes and a change in the way they have traditionally done business. 07 July 2010
Clinical results from a Phase IIb study have shown that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo in improving overall sleep efficiency in patients with primary insomnia. 18 June 2010
Vital Therapies, Inc. (VTI) has announced that the first two subjects have been enrolled at King's College Hospital, London, in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. 10 June 2010
Evotec has announced that a compound in its alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of phase I studies, Evotec will receive a milestone payment of €2 million. 20 May 2010
A new preparation of an omega-3 polyunsaturated fatty acid found naturally in fish could offer hope for thousands of patients at risk of developing an inherited form of bowel cancer. 18 March 2010
Xiaflex has recently been approved to treat progressive hand disease Dupuytren's contracture, which can affect a person’s ability to straighten and use their fingers. 05 February 2010
Novo Nordisk has announced that the FDA has granted marketing authorization for Victoza® for the treatment of type 2 diabetes in adults. 02 February 2010
The study is designed to confirm safety profile, pharmacokinetics and immunological effects and explore the impact of CYT107 on HIV-specific T-cell responses. 14 January 2010
Lowering triglyceride levels for at-risk patients: first patients enrolled in MARINE and ANCHOR Phase III clinical trials for AMR101. 12 January 2010
Cequent Pharmaceuticals, a biopharmaceutical company that develops products to deliver RNAi-based treatments for the prevention and treatment of human disease, announced recently that the FDA Center for Biologics Evaluation and Research has approved Cequent’s first investigational new drug (IND) application. 16 December 2009
ThromboGenics NV announced recently that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) age-related macular degeneration. 15 December 2009
Light Sciences Oncology is anticipating significant short-term progress in the company’s multi-front development of Aptocine™ (talaporfin sodium), a novel treatment for solid tumors and benign neoplasms, including BPH. 14 December 2009
UK-based Synexus recruited in excess of 2000 children aged between five and ten weeks of age over the course of three months, making Synexus the largest single source of subjects for a Phase III trial that investigated a paediatric vaccine against rotavirus and involved more than 3167 children across South Africa. 01 December 2009
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. 19 November 2009
Astex Therapeutics Limited recently announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to collaborate on the study of its novel small-molecule HSP90 inhibitor, AT13387, for the treatment of cancer. 06 November 2009
This will be the first evaluation of CureVac's RNActive® vaccine technology in humans. 05 November 2009
Human Genome Sciences, Inc. and GlaxoSmithKline PLC recently announced the full presentation of results from BLISS-52, the first of two Phase III trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus. 27 October 2009
New results have shown that the novel biological therapy ACZ885 (canakinumab) is significantly more effective than an injectable corticosteroid at reducing pain and preventing recurrent attacks or ‘flares’ in patients with hard-to-treat gout, one of the most painful forms of arthritis. 26 October 2009
GlaxoSmithKline (GSK) has recently announced the final results from its four-year combination therapy with Avodart and tamsulosin (CombAT) study. 16 October 2009
Data presented at the American Society of Retina Specialists Conference in New York. 12 October 2009
Olesoxime in ongoing pivotal efficacy study for amyotrophic lateral sclerosis. 08 October 2009
Orphan drug designation ensures market exclusivity for seven to ten years after market approval. 16 September 2009
AstraZeneca recently announced results from the Phase III head-to-head trial PLATO that demonstrate that ticagrelor has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events, than clopidogrel. 08 September 2009
Shire reported recently that it has completed its submission of a New Drug Application for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration. 04 September 2009
Ablynx recently announced positive results from its Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets von Willebrand factor. 01 September 2009
Genentech, Inc. announced recently that a Phase III study of Avastin® (bevacizumab) in combination with chemotherapy increased the time that women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival), compared with chemotherapy alone. 27 August 2009
79% of treatment-naïve HIV-1 infected adults taking once-daily PREZISTA (darunavir) reached an undetectable viral load (the goal of HIV treatment) at week 96, compared to 71% of adults taking lopinavir, the current standard. 19 August 2009
Biota Holdings Limited has announced successful results from the Asian Phase III clinical trials of CS-8958, its second-generation influenza treatment. CS-8958 has now been assigned the new name of ‘laninamivir’ by the World Health Organization under its International Non-proprietary Names drug identification system. 10 August 2009
Shire has recently reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. 03 August 2009
Vantia Therapeutics has announced positive results from a Phase IIa clinical trial of its lead development compound, VA106483, for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. 29 July 2009
Prostate cancer has overtaken lung cancer to become the most common cancer in men, affecting more than 35,000 men every year in the UK. Now, new UK research has confirmed that the cancer drug abiraterone provides a significant benefit for up to two-thirds of men with advanced and aggressive prostate cancer, according to a study published recently in the Journal of Clinical Oncology. 27 July 2009
Scientists at The Institute of Cancer Research and The Royal Marsden Hospital, working with pharmaceutical company AstraZeneca, have completed a Phase I clinical trial demonstrating the promise of a new type of cancer treatment. 27 July 2009
Systemic lupus erythematosus is a chronic, life-threatening autoimmune disease. Approximately five million people worldwide suffer from various forms of lupus, including systemic lupus erythematosus, and symptoms can include extreme fatigue, painful and swollen joints, unexplained fever, skin rash, and kidney problems. 23 July 2009
Actelion Ltd. has announced the launch of Zavesca® (miglustat), a licensed treatment available for people with Niemann-Pick type C (NP-C) disease, in the UK and Republic of Ireland. 22 July 2009
Apthera, Inc. announced recently that it had reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the planned Phase III clinical trial of Apthera’s lead drug, NeuVax. 20 July 2009
Email Address
Password
Forgotten login?